IMTX Immatics
- 11.920
- +0.320+2.76%
Immatics News
Mizuho Raises Immatics' Price Target to $16 From $14, Keeps Buy Rating
Immatics (IMTX) has an average rating of buy and price targets ranging from $16 to $25, according to analysts polled by Capital IQ.
Nearly 90% of patients have shrinking tumors! Immatics (IMTX.US) innovative cell therapy phase 2/3 trial is about to begin
iMA203 is a TCR-T cell developed by IMMatics' proprietary ActenGine platform and targets the melanoma antigen PRAME presented by HLA-A*02.
Immatics' Q1 Loss Narrows. Revenue Rises
Immatics (IMTX) reported a Q1 net loss Tuesday of 0.04 euros ($0.043) per diluted share, narrowing from a loss of 0.26 euros a year earlier. Three analysts polled by Capital IQ expected a loss of 0.27
6-K: Report of foreign private issuer (related to financial reporting)
Immatics: Runway Funding Company Operations Into 2027 >IMTX
Immatics: Runway Funding Company Operations Into 2027 >IMTX
Immatics 1Q Loss EUR3.05M >IMTX
Immatics 1Q Loss EUR3.05M >IMTX
Immatics 1Q Loss/Shr EUR0.04 >IMTX
Immatics 1Q Loss/Shr EUR0.04 >IMTX
Press Release: Immatics Announces First Quarter 2024 Financial Results and Business Update
Immatics Announces First Quarter 2024 Financial Results and Business Update Company Provides Clinical Data Update from Ongoing Phase 1 Clinical Trial with ACTengine(R) IMA203 TCR-T Targeting PRAME
Immatics N.V.'s (NASDAQ:IMTX) Share Price Could Signal Some Risk
Immatics N.V.'s (NASDAQ:IMTX) price-to-sales (or "P/S") ratio of 19.3x might make it look like a sell right now compared to the Biotechs industry in the United States, where around half of the compan
Maintained Buy Rating for Immatics Amid Robust Clinical Pipeline and Promising Partnerships
Immatics (NASDAQ:IMTX) Shareholders Are Still up 47% Over 1 Year Despite Pulling Back 7.9% in the Past Week
Immatics N.V. (NASDAQ:IMTX) shareholders have seen the share price descend 10% over the month. While that might be a setback, it doesn't negate the nice returns received over the last twelve months
Analysts Are Bullish on Top Healthcare Stocks: Immatics (IMTX), Vor Biopharma (VOR)
Sector Update: Health Care Stocks Gain Pre-Bell Thursday
Health care stocks were gaining pre-bell Thursday as the Health Care Select Sector SPDR Fund (XLV) was 0.1% higher and the iShares Biotechnology ETF (IBB) was up 0.7% recently. Immatics (IMTX) shares
12 Health Care Stocks Moving In Thursday's Pre-Market Session
GainersYield10 Bioscience (NASDAQ:YTEN) stock increased by 133.7% to $0.57 during Thursday's pre-market session. The market value of their outstanding shares is at $6.8 million. Immunovant (NASDAQ:IMV
Immatics N.V. Showcases Clinical Strides and Fiscal Health
Sector Update: Health Care
Health care stocks were gaining pre-bell Thursday as the Health Care Select Sector SPDR Fund (XLV) was 0.2% higher and the iShares Biotechnology ETF (IBB) was up 0.6% recently. Immatics (IMTX) shares
Immatics Swings to 2023 Net Loss, Revenue Falls -- Shares Down Pre-Bell
Immatics (IMTX) reported a full-year 2023 net loss Thursday of 1.20 euros ($1.31) per diluted share, swinging from earnings of 0.55 euros a year earlier. Analysts polled by Capital IQ expected a loss
Immatics Q4 GAAP EPS €(1.20) Down From €0.55 YoY, Revenue From Collaboration Agreements €54.00M Down From €172.83M YoY; Cash And Cash Equivalents, And Other Financial Assets Of €425.9M (~$470.6M) Expected To Provide Cash Runway Into 2027
Immatics Q4 GAAP EPS €(1.20) Down From €0.55 YoY, Revenue From Collaboration Agreements €54.00M Down From €172.83M YoY; Cash And Cash Equivalents, And Other Financial Assets Of €425.9M (~$470.6M) Expe
Press Release: Immatics Announces Full Year 2023 Financial Results and Corporate Update
Immatics Announces Full Year 2023 Financial Results and Corporate Update -- Interim clinical data update on ACTengine(R) IMA203 GEN1 (PRAME) in melanoma at RP2D in November 2023: 50% confirm
Immatics Announces Full Year 2023 Financial Results and Corporate Update
Analysis
Price Target
No Data
